宫颈癌化疗心血管毒性预防的间断时间序列试验

doi:10.11904/j.issn.1002-3070.2019.02.007

实用肿瘤学杂志 ›› 2019, Vol. 33 ›› Issue (2): 134-138.doi: 10.11904/j.issn.1002-3070.2019.02.007

宫颈癌化疗心血管毒性预防的间断时间序列试验

梁虹¹, 李奇², 王耀先², 靳红², 王铜¹, 王亚楠¹, 段雅妮^1,3, 宋敏²

1.哈尔滨医科大学中国疾病预防控制中心地方病控制中心克山病防治研究所(哈尔滨 150081);
2.哈尔滨医科大学附属肿瘤医院;
3.天津市疾病预防控制中心

收稿日期:2018-09-03 修回日期:2019-01-14 出版日期:2019-04-20 发布日期:2019-04-25
通讯作者: 王铜,E-mail:wangtong@ems.hrbmu.edu.cn
作者简介:梁虹,女,(1992-),硕士研究生,从事宫颈癌化疗心血管毒性防治的研究
基金资助:
国家自然科学基金项目(编号:81773368,81202154),黑龙江省博士后科研启动金(编号:LBH-Q17096)

Interrupted time series trial for prevention of cardiovascular toxicity induced by chemotherapy in cervical cancer

LIANG Hong¹, LI Qi², WANG Yaoxian², JIN Hong¹, WANG Tong¹, WANG Yanan¹, DUAN Yani^{1, 3}, SONG Min²

1.Institute of Keshan Disease, Chinese Center for Endemic Disease Control, Harbin Medical University, Harbin 150081, China;
2.Harbin Medical University Cancer Hospital;
3.Tianjin Centers for Disease Control and Prevention

Received:2018-09-03 Revised:2019-01-14 Online:2019-04-20 Published:2019-04-25

摘要/Abstract

摘要： 目的在已知有效措施的基础上构建一套实用可行的宫颈癌化疗CVT综合防治方案,为临床治疗提供科学指导与依据。方法 2016年11月—2018年1月对164例研究对象进行化疗前CVT发生风险及化疗后CVT评估,构建干预前后CVT发生率改变情况的ITS模型;同时比较ITS模型中干预后患者化疗前后CVT生物标志物和临床检查结果,评价干预措施的效果。结果干预前后CVT发生率改变情况的ITS模型无统计学意义(P＞0.05);超声心动图检查结果中二尖瓣E峰流速和E/A比值增大,差异均有统计学意义(P＜0.05),LVEF、FS、SV、二尖瓣A峰流速均无统计学差异(P＞0.05);心电图和双下肢动静脉超声检查结果均无统计学差异(P＞0.05);生物标志物检测结果中sICAM-1、sTM、vWF、h-FABP水平出现下降,NO、eNOS水平出现上升,差异均有统计学意义(P＜0.05);hs-CRP、E-selectin水平变化均无统计学差异(P＞0.05)。结论本研究构建的综合防治方案可在微观上改善宫颈癌化疗CVT,应扩大样本量开展进一步研究。

关键词: 间断时间序列试验, 宫颈癌, 心血管毒性, 化疗, 转化

Abstract: Objective The aim of this study was to establish a practical and feasible prevention,and a treatment scheme of cardiovascular toxicity(CVT)induced by chemotherapy in cervical cancer based on known effective measures and to provide scientific guidance and basis for clinical treatment. Methods The risk of pre-chemotherapy CVT and post-chemotherapy CVT were evaluated in 164 subjects from November 2016 to January 2018.The Interrupted time series(ITS)model of CVT incidence before and after intervention was established.The CVT biomarkers and results of clinical examination before and after chemotherapy were compared in selected patieds.The effects of measures were evaluated. Results There was no difference in the ITS model of CVT incidence before and after intervention(P＞0.05).Among echocardiography examination results,the E peak velocity of mitral valve and E/A ratio increased,and the difference was statistically significant(P＜0.05),LVEF、FS、SV and A peak velocity of mitral valve had no differences(P＞0.05).There were no differences in ECG and double lower extremities arteriovenous ultrasonography results(P＞0.05).The level of sICAM-1,sTM,vWF and h-FABP decreased(P＜0.05),the levels of NO and eNOS increased(P＜0.05);there was no significant difference in the levels of hs-CRP and E-selectin(P＞0.05). Conclusion The comprehensive prevention and treatment program established in this study can improve the cervical cancer chemotherapy CVT microscopically,and further research should be carried out by expanding the sample size.

Key words: Interrupted time series trial, Cervical cancer, Cardiovascular toxicity, Chemotherapy, Translation

中图分类号:

R737.33

梁虹, 李奇, 王耀先, 靳红, 王铜, 王亚楠, 段雅妮, 宋敏. 宫颈癌化疗心血管毒性预防的间断时间序列试验[J]. 实用肿瘤学杂志, 2019, 33(2): 134-138.

LIANG Hong, LI Qi, WANG Yaoxian, JIN Hong, WANG Tong, WANG Yanan, DUAN Yani, SONG Min. Interrupted time series trial for prevention of cardiovascular toxicity induced by chemotherapy in cervical cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 134-138.

参考文献

1 Global Burden of Disease Cancer Collaboration.Global,regional,and national cancer incidence,mortality,years of life lost,years lived with disability,and disability-adjusted life-years for 29 cancer groups,1990 to 2016: a systematic analysis for the global burden of disease study[J].JAMA Oncology,2018,4(11): 1553-1568.
2 谭先杰,郎景和.妇科恶性肿瘤化疗中的若干问题[J].中华妇产科杂志,2012,47(8): 561-563.
3 Kim H,Chung WB,Cho KI,et al.Diagnosis,treatment,and prevention of cardiovascular toxicity related to anti-cancer treatment in clinical practice: an opinion paper from the working group on cardio-oncology of the korean society of echocardiography[J].J Cardiovasc Ultrasound,2018,26(1): 1-25.
4 张波,周旭晨.《2016年欧洲心脏病学会肿瘤治疗与心血管毒性声明》解读[J].中国介入心脏病学杂志,2016,24(11): 629-631.
5 Bothwell LE,Greene JA,Podolsky SH,et al.Assessing the gold standard--lessons from the history of RCTs[J].N Engl J Med,2016,374(22): 2175-2181.
6 Bhatt DL,Mehta C.Adaptive designs for clinical trials[J].N Engl J Med,2016,375(1): 65-74.
7 邵华,王琦琦,胡跃华,等.中断时间序列分析及其在公共卫生领域中的应用[J].中华流行病学杂志,2015,36(9): 1015-1017.
8 Sales AE,Schalm C,Baylon MA,et al.Data for improvement and clinical excellence: report of an interrupted time series trial of feedback in long-term care[J].Implement Sci,2014,9(1): 1-13.
9 National Cancer Institute.Common terminology criteria for adverse events(CTCAE)version 4.03.2010.https://ctep.cancer.gov/protocolDevelopment/adverse_effects.htm.
10 Vaucher J,Marques-Vidal P,Waeber G,et al.Cytokines and hs-CRP levels in individuals treated with low-dose aspirin for cardiovascular prevention: a population-based study(CoLaus Study)[J].Cytokine,2014,66(2): 95-100.
11 Gerede DM,Güle S,Kilikap M,et al.Comparison of a qualitative measurement of heart-type fatty acid-binding protein with other cardiacmarkers as an early diagnostic marker in the diagnosis of non-ST-segment elevation myocardial infarction[J].Cardiovasc J Afr,2015,26(6): 204-209.
12 Flammer AJ,Anderson T,Celermajer DS,et al.The assessment of endothelial function: from research into clinical practice[J].Circulation,2012,126(6): 753-767.
13 Rueckschloss U,Kuerten S,Ergün S.The role of CEA-related cell adhesion molecule-1 in vascular homeostasis[J].Histochem Cell Biol,2016,146(6):657-671.
14 Polovina MM,Lip GY,Potpara TS.Endothelial(dys)function in lone atrial fibrillation[J].Curr Pharm Des,2015,21(5): 622-645.
15 刘永生,郑立文,武国东.内皮型一氧化氮合酶基因启动子-786位点多态性与原发性高血压发病相关性的研究[J].中国心血管病研究,2014,12(4): 309-312.
16 Henri C,Heinonen T,Tardif JC.The role of biomarkers in decreasing risk of cardiac toxicity after cancer therapy[J].Biomarkers in Cancer,2016,8(Suppl 2): 39-45.
17 Bhave M,Akhter N,Rosen ST.Cardiovascular toxicity of biologic agents for cancer therapy[J].Oncology,2014,28(6): 482-490.
18 EBioMedicine.2014: a year of breakthroughs for translational science[J].E Bio Medicine,2014,1(2/3): 91-92.
19 McLean RKD,Graham ID,Tetroe JM,et al.Translating research into action: an international study of the role of research funders[J].Health Res Policy Syst,2018,16(1): 44.

[1]	孙立春,李丹丹,李净,于凤玲. CCDC8和TGF-β1在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(3): 215-221.
[2]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[3]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[4]	秦岚群, 邹征云. 恶性黑色素瘤化疗研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 167-172.
[5]	常晓霞综述, 宋冰冰, 刘家仁审校. 植物化学物增加肿瘤细胞对化疗药物敏感性的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 67-72.
[6]	成海燕, 马晶, 冯紫微, 黄可金, 王玉霞, 张云艳. 抑癌基因PRDM5在HPV16病毒致宫颈鳞癌发生过程中的作用研究[J]. 实用肿瘤学杂志, 2018, 32(6): 483-487.
[7]	付艳丽, 余杨, 卫玮, 邹晶晶, 孙翔. 高危型人乳头状瘤病毒载量和Th1/Th2不均衡表达预测宫颈癌变进程的研究[J]. 实用肿瘤学杂志, 2018, 32(6): 533-537.
[8]	秦文艳综述, 卢艳审校. 宫颈癌前哨淋巴结微转移的研究进展[J]. 实用肿瘤学杂志, 2018, 32(6): 571-574.
[9]	王一然, 黄维, 尹蕾, 刘琳, 周晓平, 牛星鉴, 杨悦, 安巍巍, 姬宏飞. 中性粒细胞与淋巴细胞比值对宫颈癌患者同步放化疗疗效及预后判断的临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 404-409.
[10]	姜亮亮综述, 王晶审校. 上皮性卵巢癌远处转移的诊治进展[J]. 实用肿瘤学杂志, 2018, 32(5): 480-482.
[11]	张婷, 贾迪(综述), 杨丹(审校). 骨肉瘤的生物学治疗进展[J]. 实用肿瘤学杂志, 2018, 32(3): 254-257.
[12]	翟可可, 高媛媛, 冯晓, 许静文, 宫玉芳, 孟庆威. 术后辅助化疗后复发转移与初次诊断的IV期NSCLC一线化疗疗效分析[J]. 实用肿瘤学杂志, 2018, 32(2): 107-111.
[13]	孟志英, 于松涛, 张晶晶, 金惠敏. 宫颈癌下颌骨转移1例报告并文献复习[J]. 实用肿瘤学杂志, 2018, 32(2): 122-124.
[14]	毕琦玲, 周立红, 韩毅敏. HOX基因与妇科肿瘤的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 140-143.
[15]	杨文娟, 余静, 黄朝, 张俊红, 谢丛华. 化疗早期重度粒细胞下降与小细胞肺癌预后相关性分析[J]. 实用肿瘤学杂志, 2018, 32(1): 19-24.

宫颈癌化疗心血管毒性预防的间断时间序列试验

Interrupted time series trial for prevention of cardiovascular toxicity induced by chemotherapy in cervical cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价